nodes	percent_of_prediction	percent_of_DWPC	metapath
Captopril—systemic scleroderma—psoriasis	0.404	1	CtDrD
Captopril—REN—psoriasis	0.264	0.782	CbGaD
Captopril—ACE—psoriasis	0.0737	0.218	CbGaD
Captopril—ALB—Acitretin—psoriasis	0.0233	0.195	CbGbCtD
Captopril—ALB—Mycophenolate mofetil—psoriasis	0.0109	0.0914	CbGbCtD
Captopril—CYP2D6—Hydroxyurea—psoriasis	0.0102	0.0857	CbGbCtD
Captopril—SLC22A6—Cyclosporine—psoriasis	0.0097	0.0813	CbGbCtD
Captopril—ALB—Prednisone—psoriasis	0.00872	0.0731	CbGbCtD
Captopril—CYP2D6—Cholecalciferol—psoriasis	0.0062	0.052	CbGbCtD
Captopril—MMP9—synovial fluid—psoriasis	0.00583	0.147	CbGeAlD
Captopril—ABCB1—Mycophenolate mofetil—psoriasis	0.0057	0.0478	CbGbCtD
Captopril—SLC22A6—Methotrexate—psoriasis	0.00513	0.043	CbGbCtD
Captopril—MMP2—dermis—psoriasis	0.00503	0.127	CbGeAlD
Captopril—ABCB1—Betamethasone—psoriasis	0.00489	0.041	CbGbCtD
Captopril—ABCB1—Prednisolone—psoriasis	0.00483	0.0405	CbGbCtD
Captopril—ABCB1—Hydrocortisone—psoriasis	0.00458	0.0384	CbGbCtD
Captopril—ABCB1—Prednisone—psoriasis	0.00456	0.0382	CbGbCtD
Captopril—ALB—Methotrexate—psoriasis	0.00437	0.0367	CbGbCtD
Captopril—MMP9—dermis—psoriasis	0.00437	0.111	CbGeAlD
Captopril—MMP2—skeletal joint—psoriasis	0.00434	0.11	CbGeAlD
Captopril—ABCB1—Cyclosporine—psoriasis	0.00432	0.0362	CbGbCtD
Captopril—CYP2D6—Cyclosporine—psoriasis	0.00407	0.0341	CbGbCtD
Captopril—MMP9—skeletal joint—psoriasis	0.00377	0.0954	CbGeAlD
Captopril—ABCB1—Dexamethasone—psoriasis	0.00285	0.0239	CbGbCtD
Captopril—CYP2D6—Dexamethasone—psoriasis	0.00268	0.0225	CbGbCtD
Captopril—F2—vertebral column—psoriasis	0.00262	0.0662	CbGeAlD
Captopril—ABCB1—Methotrexate—psoriasis	0.00229	0.0192	CbGbCtD
Captopril—MMP2—skin epidermis—psoriasis	0.00211	0.0535	CbGeAlD
Captopril—ACE—skeletal joint—psoriasis	0.00201	0.0509	CbGeAlD
Captopril—MMP9—skin epidermis—psoriasis	0.00184	0.0465	CbGeAlD
Captopril—MMP2—endothelium—psoriasis	0.00153	0.0388	CbGeAlD
Captopril—MMP9—endothelium—psoriasis	0.00133	0.0337	CbGeAlD
Captopril—F2—endothelium—psoriasis	0.00116	0.0294	CbGeAlD
Captopril—ACE—endothelium—psoriasis	0.000711	0.018	CbGeAlD
Captopril—Enalapril—ACE—psoriasis	0.000705	1	CrCbGaD
Captopril—LTA4H—tendon—psoriasis	0.000703	0.0178	CbGeAlD
Captopril—MMP2—skin of body—psoriasis	0.000655	0.0166	CbGeAlD
Captopril—MMP9—skin of body—psoriasis	0.00057	0.0144	CbGeAlD
Captopril—MMP2—tendon—psoriasis	0.000499	0.0126	CbGeAlD
Captopril—MMP9—tendon—psoriasis	0.000434	0.011	CbGeAlD
Captopril—MMP2—Betamethasone—Clobetasol propionate—psoriasis	0.000155	0.0968	CbGdCrCtD
Captopril—MMP2—Dexamethasone—Clobetasol propionate—psoriasis	0.000155	0.0968	CbGdCrCtD
Captopril—MMP2—Dexamethasone—Fluocinonide—psoriasis	0.000124	0.0775	CbGdCrCtD
Captopril—MMP2—Dexamethasone—Beclomethasone—psoriasis	0.000124	0.0775	CbGdCrCtD
Captopril—MMP2—Betamethasone—Fluocinonide—psoriasis	0.000124	0.0775	CbGdCrCtD
Captopril—MMP2—Betamethasone—Beclomethasone—psoriasis	0.000124	0.0775	CbGdCrCtD
Captopril—MMP2—Dexamethasone—Fluocinolone Acetonide—psoriasis	0.000121	0.0754	CbGdCrCtD
Captopril—MMP2—Betamethasone—Fluocinolone Acetonide—psoriasis	0.000121	0.0754	CbGdCrCtD
Captopril—F2—Folate Metabolism—ICAM1—psoriasis	8.6e-05	0.0026	CbGpPWpGaD
Captopril—MMP9—AP-1 transcription factor network—IFNG—psoriasis	8.09e-05	0.00244	CbGpPWpGaD
Captopril—MMP9—LPA receptor mediated events—CXCL8—psoriasis	8.08e-05	0.00244	CbGpPWpGaD
Captopril—F2—Vitamin B12 Metabolism—IFNG—psoriasis	8.05e-05	0.00243	CbGpPWpGaD
Captopril—MMP9—amb2 Integrin signaling—IL6—psoriasis	7.9e-05	0.00239	CbGpPWpGaD
Captopril—MMP9—TWEAK Signaling Pathway—TNF—psoriasis	7.88e-05	0.00238	CbGpPWpGaD
Captopril—LTA4H—Metabolism of lipids and lipoproteins—APOE—psoriasis	7.84e-05	0.00237	CbGpPWpGaD
Captopril—MMP2—Developmental Biology—CARM1—psoriasis	7.56e-05	0.00228	CbGpPWpGaD
Captopril—MMP9—AP-1 transcription factor network—CXCL8—psoriasis	7.52e-05	0.00227	CbGpPWpGaD
Captopril—MMP9—LPA receptor mediated events—JUN—psoriasis	7.51e-05	0.00227	CbGpPWpGaD
Captopril—MMP9—Spinal Cord Injury—LEP—psoriasis	7.45e-05	0.00225	CbGpPWpGaD
Captopril—MMP9—FGF signaling pathway—STAT3—psoriasis	7.44e-05	0.00225	CbGpPWpGaD
Captopril—F2—Selenium Micronutrient Network—CRP—psoriasis	7.44e-05	0.00225	CbGpPWpGaD
Captopril—MMP2—ATF-2 transcription factor network—IL6—psoriasis	7.38e-05	0.00223	CbGpPWpGaD
Captopril—MMP2—EPH-Ephrin signaling—VEGFA—psoriasis	7.36e-05	0.00222	CbGpPWpGaD
Captopril—MMP9—AGE/RAGE pathway—JUN—psoriasis	7.33e-05	0.00221	CbGpPWpGaD
Captopril—LTA4H—Metabolism—CARM1—psoriasis	7.31e-05	0.00221	CbGpPWpGaD
Captopril—MMP9—LPA receptor mediated events—NFKB1—psoriasis	7.23e-05	0.00218	CbGpPWpGaD
Captopril—MMP2—Metabolism of proteins—REN—psoriasis	7.19e-05	0.00217	CbGpPWpGaD
Captopril—MMP9—AGE/RAGE pathway—NFKB1—psoriasis	7.05e-05	0.00213	CbGpPWpGaD
Captopril—MMP9—Validated transcriptional targets of AP1 family members Fra1 and Fra2—IL6—psoriasis	7.04e-05	0.00212	CbGpPWpGaD
Captopril—MMP9—Spinal Cord Injury—ICAM1—psoriasis	7e-05	0.00211	CbGpPWpGaD
Captopril—MMP9—AP-1 transcription factor network—JUN—psoriasis	6.99e-05	0.00211	CbGpPWpGaD
Captopril—ABCB1—HIF-1-alpha transcription factor network—CP—psoriasis	6.98e-05	0.00211	CbGpPWpGaD
Captopril—MMP9—Spinal Cord Injury—NOS2—psoriasis	6.94e-05	0.0021	CbGpPWpGaD
Captopril—SLC15A1—SLC-mediated transmembrane transport—CP—psoriasis	6.9e-05	0.00208	CbGpPWpGaD
Captopril—F2—Selenium Micronutrient Network—ICAM1—psoriasis	6.83e-05	0.00206	CbGpPWpGaD
Captopril—LTA4H—Metabolism of lipids and lipoproteins—PPARG—psoriasis	6.83e-05	0.00206	CbGpPWpGaD
Captopril—ALB—Lipoprotein metabolism—APOE—psoriasis	6.83e-05	0.00206	CbGpPWpGaD
Captopril—F2—Angiopoietin receptor Tie2-mediated signaling—NFKB1—psoriasis	6.8e-05	0.00205	CbGpPWpGaD
Captopril—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	6.76e-05	0.00204	CbGpPWpGaD
Captopril—MMP9—Regulation of nuclear beta catenin signaling and target gene transcription—CXCL8—psoriasis	6.76e-05	0.00204	CbGpPWpGaD
Captopril—MMP9—CXCR4-mediated signaling events—CD4—psoriasis	6.75e-05	0.00204	CbGpPWpGaD
Captopril—F2—Vitamin B12 Metabolism—NFKB1—psoriasis	6.69e-05	0.00202	CbGpPWpGaD
Captopril—MMP9—Endochondral Ossification—VEGFA—psoriasis	6.56e-05	0.00198	CbGpPWpGaD
Captopril—F2—Folate Metabolism—IFNG—psoriasis	6.55e-05	0.00198	CbGpPWpGaD
Captopril—F2—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	6.49e-05	0.00196	CbGpPWpGaD
Captopril—ACE—Metabolism of proteins—REN—psoriasis	6.47e-05	0.00195	CbGpPWpGaD
Captopril—MMP9—TWEAK Signaling Pathway—IL6—psoriasis	6.36e-05	0.00192	CbGpPWpGaD
Captopril—MMP9—AGE/RAGE pathway—STAT3—psoriasis	6.34e-05	0.00191	CbGpPWpGaD
Captopril—MMP9—Regulation of nuclear beta catenin signaling and target gene transcription—JUN—psoriasis	6.28e-05	0.0019	CbGpPWpGaD
Captopril—MMP2—Direct p53 effectors—JUN—psoriasis	6.12e-05	0.00185	CbGpPWpGaD
Captopril—MMP2—Betamethasone—Hydrocortisone—psoriasis	6.1e-05	0.0381	CbGdCrCtD
Captopril—MMP2—Dexamethasone—Hydrocortisone—psoriasis	6.1e-05	0.0381	CbGdCrCtD
Captopril—CYP2D6—Biological oxidations—CYP2S1—psoriasis	5.97e-05	0.0018	CbGpPWpGaD
Captopril—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	5.89e-05	0.00178	CbGpPWpGaD
Captopril—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	5.79e-05	0.00175	CbGpPWpGaD
Captopril—MMP2—Dexamethasone—Betamethasone—psoriasis	5.66e-05	0.0353	CbGdCrCtD
Captopril—MMP2—Betamethasone—Dexamethasone—psoriasis	5.66e-05	0.0353	CbGdCrCtD
Captopril—REN—Metabolism of proteins—LEP—psoriasis	5.61e-05	0.0017	CbGpPWpGaD
Captopril—MMP2—Extracellular matrix organization—ICAM1—psoriasis	5.6e-05	0.00169	CbGpPWpGaD
Captopril—ALB—Hemostasis—SERPINB8—psoriasis	5.57e-05	0.00168	CbGpPWpGaD
Captopril—MMP2—Betamethasone—Triamcinolone—psoriasis	5.53e-05	0.0345	CbGdCrCtD
Captopril—MMP2—Dexamethasone—Triamcinolone—psoriasis	5.53e-05	0.0345	CbGdCrCtD
Captopril—F2—Folate Metabolism—NFKB1—psoriasis	5.45e-05	0.00164	CbGpPWpGaD
Captopril—ABCB1—Allograft Rejection—HLA-C—psoriasis	5.39e-05	0.00163	CbGpPWpGaD
Captopril—F2—GPCR downstream signaling—HCAR2—psoriasis	5.38e-05	0.00162	CbGpPWpGaD
Captopril—ABCB1—Allograft Rejection—IL13—psoriasis	5.36e-05	0.00162	CbGpPWpGaD
Captopril—MMP9—Spinal Cord Injury—IFNG—psoriasis	5.33e-05	0.00161	CbGpPWpGaD
Captopril—ALB—Binding and Uptake of Ligands by Scavenger Receptors—APOE—psoriasis	5.32e-05	0.00161	CbGpPWpGaD
Captopril—F2—Angiopoietin receptor Tie2-mediated signaling—TNF—psoriasis	5.29e-05	0.0016	CbGpPWpGaD
Captopril—MMP2—Dexamethasone—Prednisone—psoriasis	5.25e-05	0.0328	CbGdCrCtD
Captopril—MMP2—Betamethasone—Prednisone—psoriasis	5.25e-05	0.0328	CbGdCrCtD
Captopril—MMP9—CXCR4-mediated signaling events—STAT3—psoriasis	5.23e-05	0.00158	CbGpPWpGaD
Captopril—F2—Vitamin B12 Metabolism—TNF—psoriasis	5.21e-05	0.00157	CbGpPWpGaD
Captopril—F2—Selenium Micronutrient Network—IFNG—psoriasis	5.2e-05	0.00157	CbGpPWpGaD
Captopril—MMP2—Dexamethasone—Prednisolone—psoriasis	5.13e-05	0.032	CbGdCrCtD
Captopril—MMP2—Betamethasone—Prednisolone—psoriasis	5.13e-05	0.032	CbGdCrCtD
Captopril—SLC22A6—SLC-mediated transmembrane transport—CP—psoriasis	5.12e-05	0.00155	CbGpPWpGaD
Captopril—MMP9—Developmental Biology—CARM1—psoriasis	4.96e-05	0.0015	CbGpPWpGaD
Captopril—MMP9—Spinal Cord Injury—CXCL8—psoriasis	4.95e-05	0.0015	CbGpPWpGaD
Captopril—F2—GPCR ligand binding—CCL20—psoriasis	4.94e-05	0.00149	CbGpPWpGaD
Captopril—MMP9—Signaling by SCF-KIT—TYK2—psoriasis	4.93e-05	0.00149	CbGpPWpGaD
Captopril—ABCB1—Allograft Rejection—IL17A—psoriasis	4.93e-05	0.00149	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—HCAR2—psoriasis	4.88e-05	0.00147	CbGpPWpGaD
Captopril—MMP9—EPH-Ephrin signaling—VEGFA—psoriasis	4.82e-05	0.00146	CbGpPWpGaD
Captopril—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	4.72e-05	0.00142	CbGpPWpGaD
Captopril—ALB—Folate Metabolism—CAT—psoriasis	4.68e-05	0.00141	CbGpPWpGaD
Captopril—MMP9—AP-1 transcription factor network—TP53—psoriasis	4.62e-05	0.00139	CbGpPWpGaD
Captopril—ABCB1—Allograft Rejection—IL12B—psoriasis	4.58e-05	0.00138	CbGpPWpGaD
Captopril—ALB—Vitamin B12 Metabolism—CRP—psoriasis	4.56e-05	0.00138	CbGpPWpGaD
Captopril—ALB—Lipid and lipoprotein metabolism—APOE—psoriasis	4.54e-05	0.00137	CbGpPWpGaD
Captopril—LTA4H—Metabolism—CAT—psoriasis	4.49e-05	0.00136	CbGpPWpGaD
Captopril—MMP2—Metabolism of proteins—ACE—psoriasis	4.49e-05	0.00136	CbGpPWpGaD
Captopril—ABCB1—Allograft Rejection—HLA-E—psoriasis	4.47e-05	0.00135	CbGpPWpGaD
Captopril—ALB—Vitamin B12 Metabolism—APOE—psoriasis	4.47e-05	0.00135	CbGpPWpGaD
Captopril—F2—Selenium Micronutrient Network—NFKB1—psoriasis	4.33e-05	0.00131	CbGpPWpGaD
Captopril—ALB—Folate Metabolism—IL4—psoriasis	4.3e-05	0.0013	CbGpPWpGaD
Captopril—F2—Folate Metabolism—TNF—psoriasis	4.24e-05	0.00128	CbGpPWpGaD
Captopril—MMP9—AP-1 transcription factor network—IL6—psoriasis	4.22e-05	0.00128	CbGpPWpGaD
Captopril—F2—Vitamin B12 Metabolism—IL6—psoriasis	4.2e-05	0.00127	CbGpPWpGaD
Captopril—ALB—Vitamin B12 Metabolism—ICAM1—psoriasis	4.2e-05	0.00127	CbGpPWpGaD
Captopril—MMP9—Validated targets of C-MYC transcriptional activation—TP53—psoriasis	4.19e-05	0.00127	CbGpPWpGaD
Captopril—F2—Hemostasis—ITGAL—psoriasis	4.08e-05	0.00123	CbGpPWpGaD
Captopril—MMP2—Direct p53 effectors—TP53—psoriasis	4.04e-05	0.00122	CbGpPWpGaD
Captopril—Dyspnoea—Cyclosporine—psoriasis	3.94e-05	0.000618	CcSEcCtD
Captopril—Somnolence—Cyclosporine—psoriasis	3.93e-05	0.000616	CcSEcCtD
Captopril—Musculoskeletal discomfort—Mycophenolate mofetil—psoriasis	3.93e-05	0.000616	CcSEcCtD
Captopril—Anaphylactic shock—Hydrocortisone—psoriasis	3.93e-05	0.000616	CcSEcCtD
Captopril—Tachycardia—Prednisolone—psoriasis	3.93e-05	0.000615	CcSEcCtD
Captopril—Photosensitivity reaction—Methotrexate—psoriasis	3.92e-05	0.000615	CcSEcCtD
Captopril—Asthenia—Mycophenolic acid—psoriasis	3.92e-05	0.000615	CcSEcCtD
Captopril—Insomnia—Mycophenolate mofetil—psoriasis	3.9e-05	0.000611	CcSEcCtD
Captopril—Dyspepsia—Cyclosporine—psoriasis	3.89e-05	0.00061	CcSEcCtD
Captopril—Nausea—Hydroxyurea—psoriasis	3.88e-05	0.000607	CcSEcCtD
Captopril—Paraesthesia—Mycophenolate mofetil—psoriasis	3.87e-05	0.000607	CcSEcCtD
Captopril—Pruritus—Mycophenolic acid—psoriasis	3.87e-05	0.000606	CcSEcCtD
Captopril—Shock—Hydrocortisone—psoriasis	3.87e-05	0.000606	CcSEcCtD
Captopril—MMP2—Axon guidance—TYK2—psoriasis	3.87e-05	0.00117	CbGpPWpGaD
Captopril—Myalgia—Triamcinolone—psoriasis	3.86e-05	0.000605	CcSEcCtD
Captopril—Dyspnoea—Mycophenolate mofetil—psoriasis	3.85e-05	0.000603	CcSEcCtD
Captopril—Decreased appetite—Cyclosporine—psoriasis	3.84e-05	0.000602	CcSEcCtD
Captopril—Tachycardia—Hydrocortisone—psoriasis	3.84e-05	0.000601	CcSEcCtD
Captopril—Somnolence—Mycophenolate mofetil—psoriasis	3.83e-05	0.000601	CcSEcCtD
Captopril—Flushing—Prednisone—psoriasis	3.82e-05	0.000599	CcSEcCtD
Captopril—Ill-defined disorder—Betamethasone—psoriasis	3.82e-05	0.000598	CcSEcCtD
Captopril—Ill-defined disorder—Dexamethasone—psoriasis	3.82e-05	0.000598	CcSEcCtD
Captopril—Discomfort—Triamcinolone—psoriasis	3.81e-05	0.000598	CcSEcCtD
Captopril—Fatigue—Cyclosporine—psoriasis	3.81e-05	0.000597	CcSEcCtD
Captopril—Stevens-Johnson syndrome—Methotrexate—psoriasis	3.8e-05	0.000595	CcSEcCtD
Captopril—Dyspepsia—Mycophenolate mofetil—psoriasis	3.8e-05	0.000595	CcSEcCtD
Captopril—Constipation—Cyclosporine—psoriasis	3.78e-05	0.000593	CcSEcCtD
Captopril—Dry mouth—Triamcinolone—psoriasis	3.77e-05	0.000592	CcSEcCtD
Captopril—Renal failure—Methotrexate—psoriasis	3.77e-05	0.00059	CcSEcCtD
Captopril—Angioedema—Betamethasone—psoriasis	3.76e-05	0.000589	CcSEcCtD
Captopril—Angioedema—Dexamethasone—psoriasis	3.76e-05	0.000589	CcSEcCtD
Captopril—Decreased appetite—Mycophenolate mofetil—psoriasis	3.75e-05	0.000588	CcSEcCtD
Captopril—Anorexia—Hydrocortisone—psoriasis	3.75e-05	0.000587	CcSEcCtD
Captopril—Diarrhoea—Mycophenolic acid—psoriasis	3.74e-05	0.000586	CcSEcCtD
Captopril—F2—Folate Metabolism—TP53—psoriasis	3.74e-05	0.00113	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—HCAR2—psoriasis	3.73e-05	0.00113	CbGpPWpGaD
Captopril—Stomatitis—Methotrexate—psoriasis	3.73e-05	0.000585	CcSEcCtD
Captopril—REN—Metabolism of proteins—CXCL8—psoriasis	3.73e-05	0.00113	CbGpPWpGaD
Captopril—ALB—Selenium Micronutrient Network—CAT—psoriasis	3.72e-05	0.00112	CbGpPWpGaD
Captopril—ALB—Folate Metabolism—CRP—psoriasis	3.71e-05	0.00112	CbGpPWpGaD
Captopril—Malaise—Dexamethasone—psoriasis	3.71e-05	0.000581	CcSEcCtD
Captopril—Malaise—Betamethasone—psoriasis	3.71e-05	0.000581	CcSEcCtD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	3.7e-05	0.00112	CbGpPWpGaD
Captopril—Anaphylactic shock—Triamcinolone—psoriasis	3.7e-05	0.00058	CcSEcCtD
Captopril—Syncope—Dexamethasone—psoriasis	3.69e-05	0.000578	CcSEcCtD
Captopril—Syncope—Betamethasone—psoriasis	3.69e-05	0.000578	CcSEcCtD
Captopril—Constipation—Mycophenolate mofetil—psoriasis	3.69e-05	0.000578	CcSEcCtD
Captopril—MMP9—Extracellular matrix organization—ICAM1—psoriasis	3.68e-05	0.00111	CbGpPWpGaD
Captopril—Hypotension—Hydrocortisone—psoriasis	3.67e-05	0.000575	CcSEcCtD
Captopril—Feeling abnormal—Cyclosporine—psoriasis	3.64e-05	0.000571	CcSEcCtD
Captopril—F2—Metabolism of proteins—REN—psoriasis	3.64e-05	0.0011	CbGpPWpGaD
Captopril—Shock—Triamcinolone—psoriasis	3.64e-05	0.00057	CcSEcCtD
Captopril—Insomnia—Prednisolone—psoriasis	3.64e-05	0.00057	CcSEcCtD
Captopril—Alopecia—Prednisone—psoriasis	3.64e-05	0.00057	CcSEcCtD
Captopril—Gastrointestinal pain—Cyclosporine—psoriasis	3.62e-05	0.000567	CcSEcCtD
Captopril—Loss of consciousness—Betamethasone—psoriasis	3.62e-05	0.000567	CcSEcCtD
Captopril—Loss of consciousness—Dexamethasone—psoriasis	3.62e-05	0.000567	CcSEcCtD
Captopril—Dizziness—Mycophenolic acid—psoriasis	3.61e-05	0.000566	CcSEcCtD
Captopril—MMP2—Developmental Biology—LEP—psoriasis	3.61e-05	0.00109	CbGpPWpGaD
Captopril—Paraesthesia—Prednisolone—psoriasis	3.61e-05	0.000566	CcSEcCtD
Captopril—Tachycardia—Triamcinolone—psoriasis	3.61e-05	0.000566	CcSEcCtD
Captopril—Musculoskeletal discomfort—Hydrocortisone—psoriasis	3.58e-05	0.000561	CcSEcCtD
Captopril—Agranulocytosis—Methotrexate—psoriasis	3.58e-05	0.00056	CcSEcCtD
Captopril—Feeling abnormal—Mycophenolate mofetil—psoriasis	3.55e-05	0.000557	CcSEcCtD
Captopril—Insomnia—Hydrocortisone—psoriasis	3.55e-05	0.000557	CcSEcCtD
Captopril—Paraesthesia—Hydrocortisone—psoriasis	3.53e-05	0.000553	CcSEcCtD
Captopril—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	3.53e-05	0.000553	CcSEcCtD
Captopril—SLC15A1—Transmembrane transport of small molecules—CP—psoriasis	3.51e-05	0.00106	CbGpPWpGaD
Captopril—Myalgia—Betamethasone—psoriasis	3.5e-05	0.000549	CcSEcCtD
Captopril—Myalgia—Dexamethasone—psoriasis	3.5e-05	0.000549	CcSEcCtD
Captopril—Body temperature increased—Cyclosporine—psoriasis	3.5e-05	0.000548	CcSEcCtD
Captopril—Abdominal pain—Cyclosporine—psoriasis	3.5e-05	0.000548	CcSEcCtD
Captopril—LTA4H—Metabolism—APOE—psoriasis	3.49e-05	0.00105	CbGpPWpGaD
Captopril—Vomiting—Mycophenolic acid—psoriasis	3.47e-05	0.000545	CcSEcCtD
Captopril—Discomfort—Betamethasone—psoriasis	3.46e-05	0.000542	CcSEcCtD
Captopril—Discomfort—Dexamethasone—psoriasis	3.46e-05	0.000542	CcSEcCtD
Captopril—Dyspepsia—Hydrocortisone—psoriasis	3.46e-05	0.000542	CcSEcCtD
Captopril—MMP9—Signaling by SCF-KIT—STAT3—psoriasis	3.45e-05	0.00104	CbGpPWpGaD
Captopril—MMP9—Spinal Cord Injury—TNF—psoriasis	3.45e-05	0.00104	CbGpPWpGaD
Captopril—Rash—Mycophenolic acid—psoriasis	3.45e-05	0.00054	CcSEcCtD
Captopril—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	3.45e-05	0.00104	CbGpPWpGaD
Captopril—Dermatitis—Mycophenolic acid—psoriasis	3.44e-05	0.00054	CcSEcCtD
Captopril—Hepatitis—Methotrexate—psoriasis	3.44e-05	0.000539	CcSEcCtD
Captopril—Headache—Mycophenolic acid—psoriasis	3.42e-05	0.000537	CcSEcCtD
Captopril—F2—Folate Metabolism—IL6—psoriasis	3.42e-05	0.00103	CbGpPWpGaD
Captopril—Decreased appetite—Hydrocortisone—psoriasis	3.42e-05	0.000535	CcSEcCtD
Captopril—ALB—Folate Metabolism—ICAM1—psoriasis	3.41e-05	0.00103	CbGpPWpGaD
Captopril—Pharyngitis—Methotrexate—psoriasis	3.41e-05	0.000535	CcSEcCtD
Captopril—Body temperature increased—Mycophenolate mofetil—psoriasis	3.41e-05	0.000534	CcSEcCtD
Captopril—Abdominal pain—Mycophenolate mofetil—psoriasis	3.41e-05	0.000534	CcSEcCtD
Captopril—Fatigue—Hydrocortisone—psoriasis	3.39e-05	0.000531	CcSEcCtD
Captopril—Vision blurred—Prednisone—psoriasis	3.38e-05	0.000529	CcSEcCtD
Captopril—Musculoskeletal discomfort—Triamcinolone—psoriasis	3.37e-05	0.000528	CcSEcCtD
Captopril—F2—Selenium Micronutrient Network—TNF—psoriasis	3.37e-05	0.00102	CbGpPWpGaD
Captopril—Anaphylactic shock—Dexamethasone—psoriasis	3.36e-05	0.000526	CcSEcCtD
Captopril—Anaphylactic shock—Betamethasone—psoriasis	3.36e-05	0.000526	CcSEcCtD
Captopril—ABCB1—Allograft Rejection—IL10—psoriasis	3.35e-05	0.00101	CbGpPWpGaD
Captopril—Insomnia—Triamcinolone—psoriasis	3.35e-05	0.000524	CcSEcCtD
Captopril—SLC15A1—Transmembrane transport of small molecules—CARM1—psoriasis	3.34e-05	0.00101	CbGpPWpGaD
Captopril—Ill-defined disorder—Prednisone—psoriasis	3.32e-05	0.000521	CcSEcCtD
Captopril—Paraesthesia—Triamcinolone—psoriasis	3.32e-05	0.000521	CcSEcCtD
Captopril—Feeling abnormal—Prednisolone—psoriasis	3.32e-05	0.00052	CcSEcCtD
Captopril—Anaemia—Prednisone—psoriasis	3.31e-05	0.000519	CcSEcCtD
Captopril—Shock—Dexamethasone—psoriasis	3.3e-05	0.000518	CcSEcCtD
Captopril—Shock—Betamethasone—psoriasis	3.3e-05	0.000518	CcSEcCtD
Captopril—Dyspnoea—Triamcinolone—psoriasis	3.3e-05	0.000517	CcSEcCtD
Captopril—Thrombocytopenia—Dexamethasone—psoriasis	3.29e-05	0.000515	CcSEcCtD
Captopril—Thrombocytopenia—Betamethasone—psoriasis	3.29e-05	0.000515	CcSEcCtD
Captopril—Tachycardia—Dexamethasone—psoriasis	3.28e-05	0.000514	CcSEcCtD
Captopril—Tachycardia—Betamethasone—psoriasis	3.28e-05	0.000514	CcSEcCtD
Captopril—Angioedema—Prednisone—psoriasis	3.27e-05	0.000513	CcSEcCtD
Captopril—ABCB1—Allograft Rejection—IL4—psoriasis	3.26e-05	0.000984	CbGpPWpGaD
Captopril—Dyspepsia—Triamcinolone—psoriasis	3.26e-05	0.00051	CcSEcCtD
Captopril—Erythema multiforme—Methotrexate—psoriasis	3.25e-05	0.00051	CcSEcCtD
Captopril—Nausea—Mycophenolic acid—psoriasis	3.25e-05	0.000509	CcSEcCtD
Captopril—MMP9—Signaling Pathways—TAGAP—psoriasis	3.24e-05	0.000978	CbGpPWpGaD
Captopril—Feeling abnormal—Hydrocortisone—psoriasis	3.24e-05	0.000507	CcSEcCtD
Captopril—Malaise—Prednisone—psoriasis	3.23e-05	0.000506	CcSEcCtD
Captopril—Gastrointestinal pain—Hydrocortisone—psoriasis	3.21e-05	0.000504	CcSEcCtD
Captopril—Syncope—Prednisone—psoriasis	3.21e-05	0.000503	CcSEcCtD
Captopril—Anorexia—Dexamethasone—psoriasis	3.2e-05	0.000502	CcSEcCtD
Captopril—Anorexia—Betamethasone—psoriasis	3.2e-05	0.000502	CcSEcCtD
Captopril—ALB—Vitamin B12 Metabolism—IFNG—psoriasis	3.19e-05	0.000964	CbGpPWpGaD
Captopril—Fatigue—Triamcinolone—psoriasis	3.19e-05	0.0005	CcSEcCtD
Captopril—ABCB1—Allograft Rejection—HLA-B—psoriasis	3.19e-05	0.000963	CbGpPWpGaD
Captopril—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	3.18e-05	0.000961	CbGpPWpGaD
Captopril—Asthenia—Cyclosporine—psoriasis	3.17e-05	0.000497	CcSEcCtD
Captopril—Loss of consciousness—Prednisone—psoriasis	3.15e-05	0.000493	CcSEcCtD
Captopril—MMP2—Developmental Biology—PPARG—psoriasis	3.15e-05	0.00095	CbGpPWpGaD
Captopril—Hypotension—Betamethasone—psoriasis	3.14e-05	0.000492	CcSEcCtD
Captopril—Hypotension—Dexamethasone—psoriasis	3.14e-05	0.000492	CcSEcCtD
Captopril—Pruritus—Cyclosporine—psoriasis	3.13e-05	0.00049	CcSEcCtD
Captopril—Body temperature increased—Hydrocortisone—psoriasis	3.11e-05	0.000487	CcSEcCtD
Captopril—Abdominal pain—Hydrocortisone—psoriasis	3.11e-05	0.000487	CcSEcCtD
Captopril—Asthenia—Mycophenolate mofetil—psoriasis	3.09e-05	0.000485	CcSEcCtD
Captopril—Musculoskeletal discomfort—Dexamethasone—psoriasis	3.06e-05	0.000479	CcSEcCtD
Captopril—Musculoskeletal discomfort—Betamethasone—psoriasis	3.06e-05	0.000479	CcSEcCtD
Captopril—Pruritus—Mycophenolate mofetil—psoriasis	3.05e-05	0.000478	CcSEcCtD
Captopril—Arthralgia—Prednisone—psoriasis	3.05e-05	0.000478	CcSEcCtD
Captopril—Myalgia—Prednisone—psoriasis	3.05e-05	0.000478	CcSEcCtD
Captopril—Feeling abnormal—Triamcinolone—psoriasis	3.05e-05	0.000478	CcSEcCtD
Captopril—LTA4H—Metabolism—PPARG—psoriasis	3.04e-05	0.000918	CbGpPWpGaD
Captopril—MMP9—Spinal Cord Injury—TP53—psoriasis	3.04e-05	0.000918	CbGpPWpGaD
Captopril—Alopecia—Methotrexate—psoriasis	3.04e-05	0.000476	CcSEcCtD
Captopril—Insomnia—Dexamethasone—psoriasis	3.04e-05	0.000476	CcSEcCtD
Captopril—Insomnia—Betamethasone—psoriasis	3.04e-05	0.000476	CcSEcCtD
Captopril—Diarrhoea—Cyclosporine—psoriasis	3.03e-05	0.000474	CcSEcCtD
Captopril—Paraesthesia—Betamethasone—psoriasis	3.01e-05	0.000472	CcSEcCtD
Captopril—Paraesthesia—Dexamethasone—psoriasis	3.01e-05	0.000472	CcSEcCtD
Captopril—Discomfort—Prednisone—psoriasis	3.01e-05	0.000472	CcSEcCtD
Captopril—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	2.97e-05	0.000896	CbGpPWpGaD
Captopril—Dyspepsia—Betamethasone—psoriasis	2.96e-05	0.000463	CcSEcCtD
Captopril—Dyspepsia—Dexamethasone—psoriasis	2.96e-05	0.000463	CcSEcCtD
Captopril—ABCB1—Allograft Rejection—HLA-A—psoriasis	2.95e-05	0.000892	CbGpPWpGaD
Captopril—Diarrhoea—Mycophenolate mofetil—psoriasis	2.95e-05	0.000463	CcSEcCtD
Captopril—ALB—Selenium Micronutrient Network—CRP—psoriasis	2.95e-05	0.000891	CbGpPWpGaD
Captopril—Dysgeusia—Methotrexate—psoriasis	2.93e-05	0.000459	CcSEcCtD
Captopril—Body temperature increased—Triamcinolone—psoriasis	2.92e-05	0.000458	CcSEcCtD
Captopril—Dizziness—Cyclosporine—psoriasis	2.92e-05	0.000458	CcSEcCtD
Captopril—Anaphylactic shock—Prednisone—psoriasis	2.92e-05	0.000458	CcSEcCtD
Captopril—Decreased appetite—Betamethasone—psoriasis	2.92e-05	0.000457	CcSEcCtD
Captopril—Decreased appetite—Dexamethasone—psoriasis	2.92e-05	0.000457	CcSEcCtD
Captopril—Fatigue—Betamethasone—psoriasis	2.89e-05	0.000454	CcSEcCtD
Captopril—Fatigue—Dexamethasone—psoriasis	2.89e-05	0.000454	CcSEcCtD
Captopril—F2—Signaling Pathways—HCAR2—psoriasis	2.88e-05	0.000871	CbGpPWpGaD
Captopril—Shock—Prednisone—psoriasis	2.88e-05	0.000451	CcSEcCtD
Captopril—Tachycardia—Prednisone—psoriasis	2.85e-05	0.000447	CcSEcCtD
Captopril—Dizziness—Mycophenolate mofetil—psoriasis	2.85e-05	0.000447	CcSEcCtD
Captopril—Vision blurred—Methotrexate—psoriasis	2.82e-05	0.000442	CcSEcCtD
Captopril—Asthenia—Hydrocortisone—psoriasis	2.82e-05	0.000442	CcSEcCtD
Captopril—Vomiting—Cyclosporine—psoriasis	2.81e-05	0.000441	CcSEcCtD
Captopril—F2—GPCR downstream signaling—CCL20—psoriasis	2.79e-05	0.000843	CbGpPWpGaD
Captopril—MMP2—Metabolism of proteins—LEP—psoriasis	2.79e-05	0.000842	CbGpPWpGaD
Captopril—Rash—Cyclosporine—psoriasis	2.79e-05	0.000437	CcSEcCtD
Captopril—Anorexia—Prednisone—psoriasis	2.79e-05	0.000437	CcSEcCtD
Captopril—Dermatitis—Cyclosporine—psoriasis	2.79e-05	0.000437	CcSEcCtD
Captopril—MMP9—Spinal Cord Injury—IL6—psoriasis	2.78e-05	0.00084	CbGpPWpGaD
Captopril—Pruritus—Hydrocortisone—psoriasis	2.78e-05	0.000436	CcSEcCtD
Captopril—Ill-defined disorder—Methotrexate—psoriasis	2.78e-05	0.000435	CcSEcCtD
Captopril—Headache—Cyclosporine—psoriasis	2.77e-05	0.000434	CcSEcCtD
Captopril—Anaemia—Methotrexate—psoriasis	2.77e-05	0.000434	CcSEcCtD
Captopril—Feeling abnormal—Betamethasone—psoriasis	2.77e-05	0.000434	CcSEcCtD
Captopril—Feeling abnormal—Dexamethasone—psoriasis	2.77e-05	0.000434	CcSEcCtD
Captopril—MMP2—Developmental Biology—TYK2—psoriasis	2.76e-05	0.000833	CbGpPWpGaD
Captopril—Gastrointestinal pain—Dexamethasone—psoriasis	2.75e-05	0.00043	CcSEcCtD
Captopril—Gastrointestinal pain—Betamethasone—psoriasis	2.75e-05	0.00043	CcSEcCtD
Captopril—Vomiting—Mycophenolate mofetil—psoriasis	2.74e-05	0.00043	CcSEcCtD
Captopril—MMP2—Axon guidance—VEGFA—psoriasis	2.73e-05	0.000825	CbGpPWpGaD
Captopril—Rash—Mycophenolate mofetil—psoriasis	2.72e-05	0.000426	CcSEcCtD
Captopril—F2—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	2.72e-05	0.000821	CbGpPWpGaD
Captopril—Dermatitis—Mycophenolate mofetil—psoriasis	2.72e-05	0.000426	CcSEcCtD
Captopril—F2—Selenium Micronutrient Network—IL6—psoriasis	2.72e-05	0.00082	CbGpPWpGaD
Captopril—ALB—Selenium Micronutrient Network—ICAM1—psoriasis	2.71e-05	0.000819	CbGpPWpGaD
Captopril—Headache—Mycophenolate mofetil—psoriasis	2.7e-05	0.000423	CcSEcCtD
Captopril—Malaise—Methotrexate—psoriasis	2.7e-05	0.000423	CcSEcCtD
Captopril—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	2.7e-05	0.000815	CbGpPWpGaD
Captopril—Diarrhoea—Hydrocortisone—psoriasis	2.69e-05	0.000421	CcSEcCtD
Captopril—Musculoskeletal discomfort—Prednisone—psoriasis	2.66e-05	0.000417	CcSEcCtD
Captopril—ALB—SLC-mediated transmembrane transport—CP—psoriasis	2.66e-05	0.000804	CbGpPWpGaD
Captopril—Dizziness—Prednisolone—psoriasis	2.66e-05	0.000417	CcSEcCtD
Captopril—ALB—Vitamin B12 Metabolism—NFKB1—psoriasis	2.66e-05	0.000802	CbGpPWpGaD
Captopril—Asthenia—Triamcinolone—psoriasis	2.65e-05	0.000416	CcSEcCtD
Captopril—Abdominal pain—Dexamethasone—psoriasis	2.65e-05	0.000416	CcSEcCtD
Captopril—Body temperature increased—Betamethasone—psoriasis	2.65e-05	0.000416	CcSEcCtD
Captopril—Abdominal pain—Betamethasone—psoriasis	2.65e-05	0.000416	CcSEcCtD
Captopril—Body temperature increased—Dexamethasone—psoriasis	2.65e-05	0.000416	CcSEcCtD
Captopril—Insomnia—Prednisone—psoriasis	2.64e-05	0.000414	CcSEcCtD
Captopril—Nausea—Cyclosporine—psoriasis	2.63e-05	0.000412	CcSEcCtD
Captopril—Paraesthesia—Prednisone—psoriasis	2.63e-05	0.000411	CcSEcCtD
Captopril—Pruritus—Triamcinolone—psoriasis	2.62e-05	0.00041	CcSEcCtD
Captopril—Cough—Methotrexate—psoriasis	2.61e-05	0.000409	CcSEcCtD
Captopril—F2—Peptide ligand-binding receptors—CXCL8—psoriasis	2.61e-05	0.000789	CbGpPWpGaD
Captopril—SLC22A6—Transmembrane transport of small molecules—CP—psoriasis	2.6e-05	0.000786	CbGpPWpGaD
Captopril—Dizziness—Hydrocortisone—psoriasis	2.6e-05	0.000407	CcSEcCtD
Captopril—ALB—Folate Metabolism—IFNG—psoriasis	2.6e-05	0.000784	CbGpPWpGaD
Captopril—Dyspepsia—Prednisone—psoriasis	2.57e-05	0.000403	CcSEcCtD
Captopril—Nausea—Mycophenolate mofetil—psoriasis	2.56e-05	0.000402	CcSEcCtD
Captopril—Myalgia—Methotrexate—psoriasis	2.55e-05	0.000399	CcSEcCtD
Captopril—Chest pain—Methotrexate—psoriasis	2.55e-05	0.000399	CcSEcCtD
Captopril—Arthralgia—Methotrexate—psoriasis	2.55e-05	0.000399	CcSEcCtD
Captopril—Decreased appetite—Prednisone—psoriasis	2.54e-05	0.000398	CcSEcCtD
Captopril—Rash—Prednisolone—psoriasis	2.54e-05	0.000398	CcSEcCtD
Captopril—F2—Signaling by GPCR—CCL20—psoriasis	2.54e-05	0.000766	CbGpPWpGaD
Captopril—MMP9—Axon guidance—TYK2—psoriasis	2.54e-05	0.000766	CbGpPWpGaD
Captopril—Dermatitis—Prednisolone—psoriasis	2.53e-05	0.000397	CcSEcCtD
Captopril—Fatigue—Prednisone—psoriasis	2.52e-05	0.000395	CcSEcCtD
Captopril—Headache—Prednisolone—psoriasis	2.52e-05	0.000395	CcSEcCtD
Captopril—Discomfort—Methotrexate—psoriasis	2.52e-05	0.000395	CcSEcCtD
Captopril—ACE—Metabolism of proteins—LEP—psoriasis	2.51e-05	0.000757	CbGpPWpGaD
Captopril—F2—Signaling Pathways—TAGAP—psoriasis	2.5e-05	0.000755	CbGpPWpGaD
Captopril—Constipation—Prednisone—psoriasis	2.5e-05	0.000392	CcSEcCtD
Captopril—Vomiting—Hydrocortisone—psoriasis	2.5e-05	0.000392	CcSEcCtD
Captopril—SLC22A6—Transmembrane transport of small molecules—CARM1—psoriasis	2.48e-05	0.00075	CbGpPWpGaD
Captopril—Rash—Hydrocortisone—psoriasis	2.48e-05	0.000388	CcSEcCtD
Captopril—Dermatitis—Hydrocortisone—psoriasis	2.48e-05	0.000388	CcSEcCtD
Captopril—Confusional state—Methotrexate—psoriasis	2.46e-05	0.000386	CcSEcCtD
Captopril—Headache—Hydrocortisone—psoriasis	2.46e-05	0.000386	CcSEcCtD
Captopril—Dizziness—Triamcinolone—psoriasis	2.45e-05	0.000383	CcSEcCtD
Captopril—Anaphylactic shock—Methotrexate—psoriasis	2.44e-05	0.000383	CcSEcCtD
Captopril—MMP9—Signaling by SCF-KIT—IL6—psoriasis	2.41e-05	0.000728	CbGpPWpGaD
Captopril—Feeling abnormal—Prednisone—psoriasis	2.41e-05	0.000378	CcSEcCtD
Captopril—Asthenia—Dexamethasone—psoriasis	2.41e-05	0.000377	CcSEcCtD
Captopril—Asthenia—Betamethasone—psoriasis	2.41e-05	0.000377	CcSEcCtD
Captopril—Thrombocytopenia—Methotrexate—psoriasis	2.39e-05	0.000375	CcSEcCtD
Captopril—Gastrointestinal pain—Prednisone—psoriasis	2.39e-05	0.000375	CcSEcCtD
Captopril—Nausea—Prednisolone—psoriasis	2.39e-05	0.000375	CcSEcCtD
Captopril—Pruritus—Dexamethasone—psoriasis	2.38e-05	0.000372	CcSEcCtD
Captopril—Pruritus—Betamethasone—psoriasis	2.38e-05	0.000372	CcSEcCtD
Captopril—MMP9—Developmental Biology—LEP—psoriasis	2.37e-05	0.000716	CbGpPWpGaD
Captopril—Vomiting—Triamcinolone—psoriasis	2.35e-05	0.000369	CcSEcCtD
Captopril—Nausea—Hydrocortisone—psoriasis	2.33e-05	0.000366	CcSEcCtD
Captopril—Rash—Triamcinolone—psoriasis	2.33e-05	0.000366	CcSEcCtD
Captopril—Dermatitis—Triamcinolone—psoriasis	2.33e-05	0.000365	CcSEcCtD
Captopril—Anorexia—Methotrexate—psoriasis	2.33e-05	0.000365	CcSEcCtD
Captopril—Headache—Triamcinolone—psoriasis	2.32e-05	0.000363	CcSEcCtD
Captopril—Body temperature increased—Prednisone—psoriasis	2.31e-05	0.000362	CcSEcCtD
Captopril—Abdominal pain—Prednisone—psoriasis	2.31e-05	0.000362	CcSEcCtD
Captopril—Diarrhoea—Dexamethasone—psoriasis	2.3e-05	0.00036	CcSEcCtD
Captopril—Diarrhoea—Betamethasone—psoriasis	2.3e-05	0.00036	CcSEcCtD
Captopril—Hypotension—Methotrexate—psoriasis	2.28e-05	0.000358	CcSEcCtD
Captopril—F2—Metabolism of proteins—ACE—psoriasis	2.27e-05	0.000687	CbGpPWpGaD
Captopril—Musculoskeletal discomfort—Methotrexate—psoriasis	2.23e-05	0.000349	CcSEcCtD
Captopril—Dizziness—Betamethasone—psoriasis	2.22e-05	0.000348	CcSEcCtD
Captopril—Dizziness—Dexamethasone—psoriasis	2.22e-05	0.000348	CcSEcCtD
Captopril—Insomnia—Methotrexate—psoriasis	2.21e-05	0.000346	CcSEcCtD
Captopril—Nausea—Triamcinolone—psoriasis	2.2e-05	0.000344	CcSEcCtD
Captopril—Paraesthesia—Methotrexate—psoriasis	2.19e-05	0.000344	CcSEcCtD
Captopril—Dyspnoea—Methotrexate—psoriasis	2.18e-05	0.000341	CcSEcCtD
Captopril—Somnolence—Methotrexate—psoriasis	2.17e-05	0.00034	CcSEcCtD
Captopril—ALB—Folate Metabolism—NFKB1—psoriasis	2.16e-05	0.000653	CbGpPWpGaD
Captopril—Dyspepsia—Methotrexate—psoriasis	2.15e-05	0.000337	CcSEcCtD
Captopril—MMP2—Developmental Biology—NFKB1—psoriasis	2.15e-05	0.000649	CbGpPWpGaD
Captopril—Vomiting—Dexamethasone—psoriasis	2.13e-05	0.000335	CcSEcCtD
Captopril—Vomiting—Betamethasone—psoriasis	2.13e-05	0.000335	CcSEcCtD
Captopril—Decreased appetite—Methotrexate—psoriasis	2.12e-05	0.000333	CcSEcCtD
Captopril—Rash—Dexamethasone—psoriasis	2.12e-05	0.000332	CcSEcCtD
Captopril—Rash—Betamethasone—psoriasis	2.12e-05	0.000332	CcSEcCtD
Captopril—Dermatitis—Dexamethasone—psoriasis	2.11e-05	0.000331	CcSEcCtD
Captopril—Dermatitis—Betamethasone—psoriasis	2.11e-05	0.000331	CcSEcCtD
Captopril—Fatigue—Methotrexate—psoriasis	2.11e-05	0.00033	CcSEcCtD
Captopril—Headache—Dexamethasone—psoriasis	2.1e-05	0.00033	CcSEcCtD
Captopril—Headache—Betamethasone—psoriasis	2.1e-05	0.00033	CcSEcCtD
Captopril—Asthenia—Prednisone—psoriasis	2.1e-05	0.000329	CcSEcCtD
Captopril—Pruritus—Prednisone—psoriasis	2.07e-05	0.000324	CcSEcCtD
Captopril—ALB—Vitamin B12 Metabolism—TNF—psoriasis	2.07e-05	0.000624	CbGpPWpGaD
Captopril—MMP9—Developmental Biology—PPARG—psoriasis	2.06e-05	0.000623	CbGpPWpGaD
Captopril—ALB—Selenium Micronutrient Network—IFNG—psoriasis	2.06e-05	0.000623	CbGpPWpGaD
Captopril—Feeling abnormal—Methotrexate—psoriasis	2.01e-05	0.000316	CcSEcCtD
Captopril—Diarrhoea—Prednisone—psoriasis	2e-05	0.000314	CcSEcCtD
Captopril—Gastrointestinal pain—Methotrexate—psoriasis	2e-05	0.000313	CcSEcCtD
Captopril—Nausea—Dexamethasone—psoriasis	1.99e-05	0.000313	CcSEcCtD
Captopril—Nausea—Betamethasone—psoriasis	1.99e-05	0.000313	CcSEcCtD
Captopril—ABCB1—Allograft Rejection—IFNG—psoriasis	1.97e-05	0.000595	CbGpPWpGaD
Captopril—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	1.97e-05	0.000594	CbGpPWpGaD
Captopril—MMP2—Developmental Biology—VEGFA—psoriasis	1.95e-05	0.000589	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—CCL20—psoriasis	1.94e-05	0.000586	CbGpPWpGaD
Captopril—Dizziness—Prednisone—psoriasis	1.93e-05	0.000303	CcSEcCtD
Captopril—Abdominal pain—Methotrexate—psoriasis	1.93e-05	0.000303	CcSEcCtD
Captopril—Body temperature increased—Methotrexate—psoriasis	1.93e-05	0.000303	CcSEcCtD
Captopril—MMP2—Developmental Biology—STAT3—psoriasis	1.93e-05	0.000583	CbGpPWpGaD
Captopril—MMP2—Axon guidance—IL6—psoriasis	1.89e-05	0.000571	CbGpPWpGaD
Captopril—F2—Platelet activation, signaling and aggregation—VEGFA—psoriasis	1.88e-05	0.000568	CbGpPWpGaD
Captopril—Vomiting—Prednisone—psoriasis	1.86e-05	0.000291	CcSEcCtD
Captopril—MMP2—Metabolism of proteins—CXCL8—psoriasis	1.85e-05	0.00056	CbGpPWpGaD
Captopril—Rash—Prednisone—psoriasis	1.84e-05	0.000289	CcSEcCtD
Captopril—Dermatitis—Prednisone—psoriasis	1.84e-05	0.000289	CcSEcCtD
Captopril—ABCB1—Allograft Rejection—CXCL8—psoriasis	1.83e-05	0.000553	CbGpPWpGaD
Captopril—Headache—Prednisone—psoriasis	1.83e-05	0.000287	CcSEcCtD
Captopril—MMP9—Developmental Biology—TYK2—psoriasis	1.81e-05	0.000546	CbGpPWpGaD
Captopril—MMP9—Axon guidance—VEGFA—psoriasis	1.79e-05	0.000541	CbGpPWpGaD
Captopril—Asthenia—Methotrexate—psoriasis	1.75e-05	0.000275	CcSEcCtD
Captopril—F2—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	1.75e-05	0.000529	CbGpPWpGaD
Captopril—Nausea—Prednisone—psoriasis	1.74e-05	0.000272	CcSEcCtD
Captopril—Pruritus—Methotrexate—psoriasis	1.73e-05	0.000271	CcSEcCtD
Captopril—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	1.72e-05	0.000519	CbGpPWpGaD
Captopril—ALB—Selenium Micronutrient Network—NFKB1—psoriasis	1.72e-05	0.000518	CbGpPWpGaD
Captopril—ALB—Platelet degranulation—VEGFA—psoriasis	1.68e-05	0.000508	CbGpPWpGaD
Captopril—ALB—Folate Metabolism—TNF—psoriasis	1.68e-05	0.000508	CbGpPWpGaD
Captopril—F2—Hemostasis—NOS2—psoriasis	1.67e-05	0.000505	CbGpPWpGaD
Captopril—Diarrhoea—Methotrexate—psoriasis	1.67e-05	0.000262	CcSEcCtD
Captopril—MMP2—Developmental Biology—TNF—psoriasis	1.67e-05	0.000505	CbGpPWpGaD
Captopril—ALB—Vitamin B12 Metabolism—IL6—psoriasis	1.67e-05	0.000503	CbGpPWpGaD
Captopril—ACE—Metabolism of proteins—CXCL8—psoriasis	1.67e-05	0.000503	CbGpPWpGaD
Captopril—ALB—Hemostasis—ITGAL—psoriasis	1.62e-05	0.000489	CbGpPWpGaD
Captopril—Dizziness—Methotrexate—psoriasis	1.62e-05	0.000253	CcSEcCtD
Captopril—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—psoriasis	1.6e-05	0.000484	CbGpPWpGaD
Captopril—Vomiting—Methotrexate—psoriasis	1.55e-05	0.000243	CcSEcCtD
Captopril—Rash—Methotrexate—psoriasis	1.54e-05	0.000241	CcSEcCtD
Captopril—Dermatitis—Methotrexate—psoriasis	1.54e-05	0.000241	CcSEcCtD
Captopril—Headache—Methotrexate—psoriasis	1.53e-05	0.00024	CcSEcCtD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	1.51e-05	0.000456	CbGpPWpGaD
Captopril—F2—Signaling Pathways—CCL20—psoriasis	1.5e-05	0.000452	CbGpPWpGaD
Captopril—ABCB1—Allograft Rejection—VEGFA—psoriasis	1.49e-05	0.000449	CbGpPWpGaD
Captopril—ALB—Folate Metabolism—TP53—psoriasis	1.48e-05	0.000448	CbGpPWpGaD
Captopril—ALB—Metabolism—NDUFA5—psoriasis	1.46e-05	0.000439	CbGpPWpGaD
Captopril—Nausea—Methotrexate—psoriasis	1.45e-05	0.000227	CcSEcCtD
Captopril—F2—Metabolism of proteins—LEP—psoriasis	1.41e-05	0.000426	CbGpPWpGaD
Captopril—MMP9—Developmental Biology—NFKB1—psoriasis	1.41e-05	0.000426	CbGpPWpGaD
Captopril—ALB—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.36e-05	0.00041	CbGpPWpGaD
Captopril—ALB—Folate Metabolism—IL6—psoriasis	1.36e-05	0.00041	CbGpPWpGaD
Captopril—ALB—Transmembrane transport of small molecules—CP—psoriasis	1.35e-05	0.000408	CbGpPWpGaD
Captopril—MMP2—Developmental Biology—IL6—psoriasis	1.35e-05	0.000407	CbGpPWpGaD
Captopril—ALB—Selenium Micronutrient Network—TNF—psoriasis	1.34e-05	0.000403	CbGpPWpGaD
Captopril—F2—GPCR ligand binding—CXCL8—psoriasis	1.33e-05	0.000403	CbGpPWpGaD
Captopril—F2—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	1.33e-05	0.000401	CbGpPWpGaD
Captopril—ALB—Transmembrane transport of small molecules—CARM1—psoriasis	1.29e-05	0.00039	CbGpPWpGaD
Captopril—MMP9—Developmental Biology—VEGFA—psoriasis	1.28e-05	0.000386	CbGpPWpGaD
Captopril—ABCB1—Allograft Rejection—TNF—psoriasis	1.28e-05	0.000385	CbGpPWpGaD
Captopril—ABCB1—Metabolism—NDUFA5—psoriasis	1.28e-05	0.000385	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	1.27e-05	0.000383	CbGpPWpGaD
Captopril—MMP9—Developmental Biology—STAT3—psoriasis	1.27e-05	0.000383	CbGpPWpGaD
Captopril—MMP9—Axon guidance—IL6—psoriasis	1.24e-05	0.000374	CbGpPWpGaD
Captopril—ALB—Metabolism—CYP2S1—psoriasis	1.24e-05	0.000374	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—NDUFA5—psoriasis	1.2e-05	0.000363	CbGpPWpGaD
Captopril—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	1.19e-05	0.000358	CbGpPWpGaD
Captopril—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	1.13e-05	0.000341	CbGpPWpGaD
Captopril—MMP9—Developmental Biology—TNF—psoriasis	1.1e-05	0.000331	CbGpPWpGaD
Captopril—ABCB1—Metabolism—CYP2S1—psoriasis	1.08e-05	0.000327	CbGpPWpGaD
Captopril—ALB—Selenium Micronutrient Network—IL6—psoriasis	1.08e-05	0.000325	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—SOCS1—psoriasis	1.07e-05	0.000323	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—CYP2S1—psoriasis	1.02e-05	0.000309	CbGpPWpGaD
Captopril—F2—Hemostasis—VEGFA—psoriasis	9.69e-06	0.000293	CbGpPWpGaD
Captopril—F2—Metabolism of proteins—CXCL8—psoriasis	9.39e-06	0.000283	CbGpPWpGaD
Captopril—MMP9—Developmental Biology—IL6—psoriasis	8.85e-06	0.000267	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	8.41e-06	0.000254	CbGpPWpGaD
Captopril—F2—Signaling Pathways—SOCS1—psoriasis	8.25e-06	0.000249	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	8.09e-06	0.000244	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—APOE—psoriasis	7.88e-06	0.000238	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—LEP—psoriasis	7.88e-06	0.000238	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—TYK2—psoriasis	7.86e-06	0.000237	CbGpPWpGaD
Captopril—F2—GPCR downstream signaling—CXCL8—psoriasis	7.54e-06	0.000228	CbGpPWpGaD
Captopril—ALB—Platelet activation, signaling and aggregation—VEGFA—psoriasis	7.46e-06	0.000225	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—NFKBIA—psoriasis	7.35e-06	0.000222	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	7.35e-06	0.000222	CbGpPWpGaD
Captopril—F2—Hemostasis—TP53—psoriasis	7.32e-06	0.000221	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—CXCL8—psoriasis	6.85e-06	0.000207	CbGpPWpGaD
Captopril—ALB—Hemostasis—NOS2—psoriasis	6.64e-06	0.0002	CbGpPWpGaD
Captopril—ALB—Metabolism of lipids and lipoproteins—APOE—psoriasis	6.49e-06	0.000196	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	6.29e-06	0.00019	CbGpPWpGaD
Captopril—F2—Signaling Pathways—LEP—psoriasis	6.09e-06	0.000184	CbGpPWpGaD
Captopril—F2—Signaling Pathways—APOE—psoriasis	6.09e-06	0.000184	CbGpPWpGaD
Captopril—ALB—Metabolism—CARM1—psoriasis	6.04e-06	0.000182	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—TYK2—psoriasis	6.02e-06	0.000182	CbGpPWpGaD
Captopril—F2—Signaling Pathways—NFKBIA—psoriasis	5.67e-06	0.000171	CbGpPWpGaD
Captopril—ALB—Metabolism of lipids and lipoproteins—PPARG—psoriasis	5.65e-06	0.000171	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	5.55e-06	0.000168	CbGpPWpGaD
Captopril—ABCB1—Metabolism—CARM1—psoriasis	5.3e-06	0.00016	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—CXCL8—psoriasis	5.24e-06	0.000158	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—CARM1—psoriasis	4.99e-06	0.000151	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—JUN—psoriasis	4.87e-06	0.000147	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—NFKB1—psoriasis	4.69e-06	0.000142	CbGpPWpGaD
Captopril—F2—Signaling Pathways—TYK2—psoriasis	4.65e-06	0.00014	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—VEGFA—psoriasis	4.25e-06	0.000128	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—STAT3—psoriasis	4.21e-06	0.000127	CbGpPWpGaD
Captopril—F2—Signaling Pathways—CXCL8—psoriasis	4.04e-06	0.000122	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—IL6—psoriasis	3.85e-06	0.000116	CbGpPWpGaD
Captopril—ALB—Hemostasis—VEGFA—psoriasis	3.85e-06	0.000116	CbGpPWpGaD
Captopril—F2—Signaling Pathways—JUN—psoriasis	3.76e-06	0.000114	CbGpPWpGaD
Captopril—ALB—Metabolism—CAT—psoriasis	3.72e-06	0.000112	CbGpPWpGaD
Captopril—F2—Signaling Pathways—NFKB1—psoriasis	3.62e-06	0.000109	CbGpPWpGaD
Captopril—F2—Signaling Pathways—VEGFA—psoriasis	3.29e-06	9.92e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—CAT—psoriasis	3.26e-06	9.83e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—STAT3—psoriasis	3.25e-06	9.82e-05	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—TP53—psoriasis	3.22e-06	9.71e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—CAT—psoriasis	3.07e-06	9.27e-05	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—IL6—psoriasis	2.94e-06	8.89e-05	CbGpPWpGaD
Captopril—ALB—Hemostasis—TP53—psoriasis	2.91e-06	8.77e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—APOE—psoriasis	2.89e-06	8.72e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—APOE—psoriasis	2.53e-06	7.64e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—PPARG—psoriasis	2.52e-06	7.6e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—TP53—psoriasis	2.48e-06	7.5e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—APOE—psoriasis	2.38e-06	7.2e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—IL6—psoriasis	2.27e-06	6.86e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—PPARG—psoriasis	2.2e-06	6.66e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—PPARG—psoriasis	2.08e-06	6.27e-05	CbGpPWpGaD
